Why the study?
The cusp-overlap view was adopted to reduce permanent pacemaker implantation risk after TAVI with self-expandable valves, but comparative evidence regarding its effectiveness and safety remains scarce.
Does the cusp-overlap view technique reduce post-procedural permanent pacemaker implantation in patients undergoing TAVI with self-expandable valves compared to the standard coplanar view?
Does the cusp-overlap view technique reduce post-procedural permanent pacemaker implantation in patients undergoing TAVI with self-expandable valves compared to the standard coplanar view?
The use of the cusp-overlap view during TAVI with self-expandable valves significantly reduces the risk of permanent pacemaker implantation without increasing the risk of other procedural complications compared to the standard coplanar view.
Supports cusp-overlap view adoption in TAVI with self-expandable valves to reduce PPI; extends meta-analytic evidence for procedural optimization.
BACKGROUND: Permanent pacemaker implantation (PPI) is a common complication after transcatheter aortic valve implantation (TAVI). The cusp-overlap view (COV) was adopted to reduce PPI risk after TAVI with self-expandable valves (SEVs); however, the evidence remains scarce. We performed a systematic review with meta-analysis comparing COV and the standard coplanar view (CPV) technique to evaluate their effectiveness and safety. METHODS: Following the PRISMA statement, data were extracted from studies published by August 2022 and found in PubMed/MEDLINE, EMBASE, CENTRAL/CCTR, ClinicalTrials.gov, SciELO, LILACS, and Google Scholar. The primary outcome of interest was post-procedural PPI and the secondary outcomes were new left bundle branch block (LBBB), moderate/severe paravalvular leak (PVL), valve dislocation (pop-out); need of second transcatheter heart valve, 30-day mortality, stroke, conversion to surgery, coronary obstruction, implantation depth (mm), and post-TAVI mean gradients (mmHg). RESULTS: Eleven studies met our eligibility criteria and included 1464 patients in the COV group and 1743 patients in the CPV group. Patients who underwent TAVI with COV had lower risk of PPI (odds ratio 0.48; 95% confidence interval [CI] 0.33-0.70; p = 0.001) and higher implantation depths with COV (mean difference -0.83; 95% CI -1.2 to -0.45; p < 0.001). We did not observe any statistically significant differences in the rates of new LBBB, moderate/severe PVL, valve dislocation, need of second transcatheter heart valve, 30-day mortality, stroke, conversion to surgery, coronary obstruction, and post-TAVI mean gradients (mmHg). CONCLUSION: In TAVI with SEVs, the application of COV is associated with lower risk of PPI compared with the standard CPV without increasing risk for adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Sá et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: